Our results confirmed that EpCAM-ReTARGTPR effectively engaged CMV-specific CD8pos T cells to eliminate EpCAMpos cancer cells with potency comparable to solitomab, without inducing excessive cytokine release. The gene discussed is EPCAM; the disease is cancer.